Dublin, July 11, 2018 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets in US$ Million. The global market is analyzed by the following Drug Class and Brands:
- Endothelin Receptor Antagonist (Letairis/Volibris, Macitentan, Thelin, & Tracleer)
- Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri*, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis, & Orenitram)
- PDE-5 Inhibitors (Cialis/Adcirca, & Revatio)
- Soluble Guanylate Cyclase (sGC) Stimulator (Riociguat)
The report profiles 31 companies including many key and niche players such as:
- Actelion Pharmaceuticals Ltd (Switzerland)
- Bayer AG (Germany)
- Gilead Sciences, Inc. (US)
- Pfizer, Inc. (US)
- United Therapeutics Corporation (US)
- Lung Biotechnology PBC (US)
Key Topics Covered
1. INDUSTRY OVERVIEW Pulmonary Arterial Hypertension (PAH) A Prelude Current & Future Analysis PAH Drugs Market by Class The PAH Classification PH Patient Groupings as per World Health Organization Classification of PAH patients as per New York Heart Association (NYHA) Oral Therapies lead the Global PAH Therapeutics Market Combination Therapy Favored over Monotherapy for PAH Pediatric PAH A Potential Market with Unmet Need Inflammation: New Target for PAH Therapeutics Aging Population & PAH 2. COMPETITIVE SCENARIO Leading Players Leading Approved Drugs as Per Mode of Administration Major Drug Brands by Class Prostacyclin receptor agonist/ Prostacyclin Analogue Flolan (Epoprostenol) Ventavis (Iloprost) Remodulin (Treprostinil) Orenitram Tyvaso Uptravi (Selexipag) Veletri (Epoprostenol for Injection) Phosphodiesterase 5 inhibitor Revatio Adcirca (Tadalafil) Endothelin receptor antagonists (ERAs) Opsumit Tracleer (Bosentan) Letairis (Ambrisentan) Loss of Market exclusivity Tones Down Growth Patent Expiry of Leading PAH Drugs Opsumit & Uptravi: Game-changers for Actelion Selexipag Latest Entrant in PAH Therapeutics United Therapeutics A Major Player Gilead Sciences GlaxoSmithKline Bayer 3. PAH PIPELINE Pulmokine Investigates PDGF Receptor Pathway Reata Pharmaceuticals Completes Phase 3 Study for Bardoxolone methyl Eiger BioPharmaceuticals Commences Phase 2 Trials for Bestatin Insmed Investigates INS 1009 LTT Bio-Pharma Focuses on LT-2004 Ascendis Investigates TransCon Treprostinil in a Phase I trial Arena Initiates Phase II Trial for Ralinepeg, TheraSilence nanoparticles Found to Reduce Pulmonary Arterial Thickness CXA-10 to Undergo Phase II Study Atu111 Undergoes Preclinical Trial for PH RP5063 A NCE for PAH SteadyMed to File NDA for Trevyent Pluristem's PLX-PAD Sagene Pharmaceuticals, Inc. Select PAH Therapeutics under Pipeline: 2016 4. PRODUCT OVERVIEW 5. PRODUCT INNOVATIONS & APPROVALS Nippon Shinyaku Receives Marketing Approval for Uptravi Actelion to Initiate Phase III Study for Pediatric Formulation of Opsumit Actelion Announces USFDA Approval of Uptravi Reata Pharmaceuticals' Bardoxolone Methyl Receives Orphan Drug Designation Actelion Receives Approval for Opsumit from Japan's MHLW Bayer Healthcare Receives Approval for Adempas from Japan's MHLW Silence Therapeutics Develops Gene Toolkit for PAH Research Arena Pharmaceuticals' APD811 Receives Orphan Drug Status for PAH Treatment Bayer's Adempas Approved for Two Rare Types of PAH Actelion's Opsumit Receives Approval from Australia's TGA 6. RECENT INDUSTRY ACTIVITY Arena Pharmaceuticals Initiates Phase 2 Clinical Trial for Ralinepag Gilead Reports Top-Line Phase 2 Results for GS-4997 ( Selonsertib) in Pulmonary Arterial Hypertension (PAH) Gilead Sciences Accelerates its PAH Portfolio Mallinckrodt Pharmaceuticals Acquires Ikaria Supernus Pharmaceuticals Receives US$2 million Milestone Payment from United Therapeutics Vectura Group plc Acquires Activaero GmbH Mast Therapeutics Completes Acquisition of Aires Pharmaceuticals 7. FOCUS ON SELECT GLOBAL PLAYERS Actelion Pharmaceuticals Ltd (Switzerland) Bayer AG (Germany) Gilead Sciences, Inc. (US) Pfizer, Inc. (US) United Therapeutics Corporation (US) Lung Biotechnology PBC (US) 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 31 (including Divisions/Subsidiaries 33)
- The United States (18)
- Japan (3)
- Europe (10)
- France (1)
- Germany (3)
- The United Kingdom (3)
- Rest of Europe (3)
- Asia-Pacific (Excluding Japan) (1)
- Middle East (1)
For more information about this report visit https://www.researchandmarkets.com/research/h...onary?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Cardiovascular Drugs